Combined Immunodeficiency

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-12-18
EMA Authorised: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells) — Fondazione Telethon ETS
EMA authorised Strimvelis for the treatment of severe combined immunodeficiency due to ADA deficiency (ADA-SCID); the marketing authorizatio…